Y-Intercept (HK)’s Aurinia Pharmaceuticals AUPH Stock Holding History

Y-Intercept (HK)’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.05M	Buy	120,824 +49,366	+69%	+$789K	0.04%	689
2026 Q1	$1.06M	Buy	+71,458	New	+$1.04M	0.02%	1011
2025 Q2	–	Sell	-17,410	Closed	-$140K	–	1624
2025 Q1	$140K	Buy	+17,410	New	+$141K	0.01%	1090
2023 Q2	–	Sell	-10,586	Closed	-$116K	–	1258
2023 Q1	$116K	Sell	10,586 -6,210	-37%	-$54.7K	0.01%	1039
2022 Q4	$72.6K	Buy	+16,796	New	+$97.5K	0.01%	906

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Y-Intercept (HK)'s AUPH Position: Q2 2026 in Review

Y-Intercept (HK) increased its Aurinia Pharmaceuticals (AUPH) stake by 69% in Q2 2026, buying an estimated $789K and bringing the position to 120,824 shares worth $2.05M. The position accounts for 0.04% of the portfolio, ranked #689.

Y-Intercept (HK) first reported a position in AUPH in Q4 2022 and has held it in 5 quarters since. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Y-Intercept (HK) held 120,824 shares of Aurinia Pharmaceuticals worth $2.05M as of Q2 2026.
Y-Intercept (HK) bought 49,366 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $789K.
Aurinia Pharmaceuticals made up 0.04% of Y-Intercept (HK)'s portfolio in Q2 2026, its #689 holding.
Y-Intercept (HK) first reported a position in Aurinia Pharmaceuticals in Q4 2022 and has held it in 5 quarters since.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.